Telix Pharmaceuticals Limited
TLPPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $5 | $8 | $6 | $3 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $0 | $1 | $0 | $0 |
| Enterprise Value | $6 | $8 | $6 | $3 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | -0.2% | 214.5% | -32.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 48.6% | 64.9% | 65.6% | 79.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 1.5% | 12.9% | 21.3% | 8.2% |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -0.6% | 6.4% | 6.2% | 6.9% |
| EPS Diluted | -0.01 | 0.11 | 0.033 | 0.06 |
| % Growth | -109.4% | 230.3% | -44.8% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | $0 |